Capital Analysts LLC Grows Position in Medtronic PLC $MDT

Capital Analysts LLC raised its stake in shares of Medtronic PLC (NYSE:MDT) by 5.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 168,785 shares of the medical technology company’s stock after purchasing an additional 9,294 shares during the period. Capital Analysts LLC’s holdings in Medtronic were worth $13,204,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after buying an additional 37,265 shares during the period. Sivia Capital Partners LLC raised its position in shares of Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after buying an additional 381 shares during the period. Jump Financial LLC purchased a new position in shares of Medtronic in the 2nd quarter worth $299,000. Main Street Financial Solutions LLC boosted its holdings in Medtronic by 28.9% in the second quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock valued at $1,251,000 after acquiring an additional 3,218 shares during the last quarter. Finally, HUB Investment Partners LLC boosted its holdings in Medtronic by 21.3% in the second quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock valued at $1,676,000 after acquiring an additional 3,376 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of NYSE MDT opened at $92.41 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a market capitalization of $118.20 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 2.21 and a beta of 0.56. The business has a 50-day moving average of $87.33 and a 200-day moving average of $85.21.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The firm had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. During the same quarter in the prior year, the business earned $1.26 EPS. Medtronic’s quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts anticipate that Medtronic PLC will post 5.96 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Truist Financial reissued a “hold” rating and set a $99.00 price target (up from $86.00) on shares of Medtronic in a research report on Wednesday, September 2nd. Stifel Nicolaus lifted their price objective on Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a research note on Wednesday, September 2nd. Rothschild & Co Redburn decreased their target price on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a report on Friday, June 5th. Leerink Partners dropped their target price on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a research report on Thursday, June 4th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $92.00 price target on shares of Medtronic in a report on Thursday, September 3rd. Nineteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and an average target price of $103.92.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.